Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: A relevant pending task for vaccine development

International Reviews of Immunology

Volumn 31, Issue 3, 2012, Pages 223-242

  Alvarez Lajonchere, Liz ^a   Dueñas Carrera, Santiago ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Antibodies; HCV; Immunity; Reinfection; Specificity; T cell; Vaccine

Indexed keywords

ANTIBODY; CHRONVAC C; CIGB 230; GI 5005; HEPATITIS C VACCINE; IC 41; ISA 51; ISCOMATRIX; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; CHIMPANZEE; CORRELATION ANALYSIS; DRUG RESEARCH; GENETIC ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; MEDICAL INFORMATION; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REINFECTION; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION; VIRAL CLEARANCE;

ANIMALS; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MICE; PAN TROGLODYTES; VACCINATION; VIRAL HEPATITIS VACCINES;

EID: 84862083480     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.680552     Document Type: Review

References (123)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-538. (Pubitemid 44307383)
2. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127(5):1372-1380. (Pubitemid 39457763)
3. Ghany MG, Strader DB,Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
4. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995;346(8981):1006-1007.
5. KaplanDE, Sugimoto K,Newton K, et al.Discordant role ofCD4T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology. 2007;132(2):654-666. (Pubitemid 46274664)
6. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A. 2002;99(24):15661-15668. (Pubitemid 35403988)
7. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34-41.
8. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450-456. (Pubitemid 30484478)
9. Chang KM,Thimme R, Melpolder JJ, et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 2001;33(1):267-276. (Pubitemid 32016910)
10. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol. 2000;30(9):2479-2487.
11. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1996;98(3):706-714. (Pubitemid 26349175)
12. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6(5):578-582. (Pubitemid 30305910)
13. Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine. 2006;24(20):4343-53.
14. Habersetzer F, Honnet G, Bain C, et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology. 2011;141(3):890-899.
15. Nevens F, Roskams T, van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology. 2003;38(5):1289-1296. (Pubitemid 37314839)
16. Alvarez-Lajonchere L, Shoukry NH, Gra B, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, inHCV-chronically infected individuals in a phase I clinical trial. J ViralHepat. 2009;16(3):156-167.
17. + T cells in healthy individuals and chronic hepatitis C patients. Vaccine. 2007;25(37-38):6793-6806. (Pubitemid 47332723)
18. CastellanosM, Cinza Z,Dorta Z, et al. Immunizationwith aDNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after antihepatitis B vaccination. J GeneMed. 2010;12(1):107-116.
19. Frey SE, HoughtonM, Coates S, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28(38):6367-6373.
20. Klade CS,WedemeyerH, Berg T, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology. 2008;134(5):1385-1395.
21. Bailey J. An assessment of the use of chimpanzees in hepatitis C research past, present and future, 2: alternative replacement methods. Altern Lab Anim. 2010;38(6):471-494.
22. Yu C, Boon D, McDonald SL, et al. Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences. J Virol. 2010;84(21):11264-11278.
23. Yu CI, Chiang BL. A new insight into hepatitis C vaccine development. J Biomed Biotechnol. 2010;2010:548280.
24. + T cells are required for protection from persistent hepatitis C virus infection. J ExpMed. 2003;197(12):1645-1655. (Pubitemid 36745340)
25. Nanda S, HavertMB, Calderon GM, et al. Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS ONE. 2008;3(10):e3442.
26. Watanabe H, Wells F, Major ME. Clearance of hepatitis C in chimpanzees is associated with intrahepatic T-cell perforin expression during the late acute phase. J Viral Hepat. 2010;17(4):245-253.
27. Sugitani M, Nishimura S,Mizuno K, Shikata T. Analyses of amino acid sequences in hypervariable region-1 of hepatitis C virus (HCV) in sera from chimpanzees infected three times with the same HCV strain. JMed Primatol. 2010;39(1):1-8.
28. Bukh J,ThimmeR,Meunier JC, et al.Previously infected chimpanzees arenot consistentlyprotected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol. 2008;82(16):8183-8195.
29. Prince AM, Brotman B, Lee DH, et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis. 2005;192(10):1701-1709. (Pubitemid 41587819)
30. Barth H, Rybczynska J, Patient R, et al. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology. 2011;54(4):1135-1148.
31. Uebelhoer L,Han JH, Callendret B, et al. Stable cytotoxic T cell escapemutation in hepatitis C virus is linked tomaintenance of viral fitness. PLoS Pathog. 2008;4(9):e1000143.
32. Duan H, Struble E, Zhong L, et al. Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccineinduced antibodies. Vaccine. 2010;28(25):4138-4144.
33. + immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology. 2006;44(3):736-745. (Pubitemid 44433731)
34. Fuller MJ, Shoukry NH, Gushima T, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology. 2010;51(2):378-387.
35. Youn JW, Park SH, Lavillette D, et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology. 2005;42(6):1429-1436. (Pubitemid 43260047)
36. Verstrepen BE,Depla E, Rollier CS, et al. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis. 2011;204(6):837-844.
37. Elmowalid GA, Qiao M, Jeong SH, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A. 2007;104(20):8427-8432. (Pubitemid 47175504)
38. Youn JW, Hu YW, Tricoche N, et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol. 2008;82(21):10896-10905. (Pubitemid 352691168)
39. Zubkova I, Choi YH, Chang E, et al. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine. 2009;27(19):2594-2602.
40. Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. NatMed. 2006;12(2):190-197. (Pubitemid 43214745)
41. Rollier CS, Paranhos-Baccala G, Verschoor EJ, et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology. 2007;45(3):602-613. (Pubitemid 46450611)
42. Koike K,Moriya K,Matsuura Y. Animalmodels for hepatitis C and related liver disease. Hepatol Res. 2010;40(1):69-82.
43. Tong Y, Zhu Y, Xia X, et al. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol. 2011,85(6):2793-2802.
44. Washburn ML, Bility MT, Zhang L, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology. 2011;140(4):1334-1344.
45. Osburn WO, Fisher BE, Dowd KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138(1):315-324.
46. Guobuzaite A, Chokshi S, Balciuniene L, et al. Viral clearance or persistence after acute hepatitis C infection: interim results froma prospective study.Medicina (Kaunas). 2008;44(7):510-520.
47. Kamal SM, Amin A,Madwar M, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol. 2004;78(22):12252-12258. (Pubitemid 39458745)
48. + T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol. 1999;162(11):6681-6689. (Pubitemid 29309393)
49. Thimme R, Lohmann V,Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res. 2006;69(3):129-141. (Pubitemid 43247333)
50. + T cell responses during longitudinal study of acute human hepatitis C. Hepatology. 2005;42(1):104-112. (Pubitemid 40911317)
51. Thurairajah P, Hegazy D, Chokshi S, et al. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis. 2008;198(12):1749-1755.
52. Mizukoshi E, Eisenbach C, Edlin BR, et al. Hepatitis C virus (HCV)-specific immune responses of long-terminjection drug users frequently exposed to HCV. J Infect Dis. 2008;198(2):203-212. (Pubitemid 352019285)
53. + T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002;35(1):190-198. (Pubitemid 34032560)
54. Neveu B, Debeaupuis E, Echasserieau K, et al. Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology. 2008;48(3):713-722.
55. Yerly D, Heckerman D, Allen TM, et al. Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol. 2008;82(6):3147-3153. (Pubitemid 351329204)
56. + T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670-684. (Pubitemid 47615511)
57. Rutebemberwa A, Ray SC, Astemborski J, et al. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associatedwith viral persistence and require preservation of cognate antigen during chronic infection. J Immunol. 2008;181(12):8215-8225.
58. Golden-Mason L, Klarquist J,Wahed AS, Rosen HR. Cutting edge: programmed death-1 expression is increased onimmunocytes in chronic hepatitisCvirus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol. 2008;180(6):3637-3641.
59. + T cells during acute HCV infection, irrespective of clinical outcome. J Virol. 2008;82(6):3154-3160. (Pubitemid 351329205)
60. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436(7053):946-952. (Pubitemid 41191670)
61. Christie JM, Healey CJ,Watson J, et al. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol. 1997;110(1):4-8. (Pubitemid 27428507)
62. Post JJ, Pan Y, Freeman AJ, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis. 2004;189(10):1846-1855. (Pubitemid 38657221)
63. Logvinoff C, Major ME, Oldach D, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A. 2004;101(27):10149-10154. (Pubitemid 38891210)
64. Steinmann D, Barth H, Gissler B, et al. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol. 2004;78(17):9030-9040. (Pubitemid 39096514)
65. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology. 2009;136(7):2377-2386.
66. Lavillette D, Morice Y, Germanidis G, et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol. 2005;79(10):6023-6034. (Pubitemid 40617208)
67. Sasayama M, Deng L, Kim SR, Ide Y, Shoji I, Hotta H. Analysis of neutralizing antibodies against hepatitis C virus in patients who were treated with pegylated-interferon plus ribavirin. Kobe JMed Sci. 2010;56(2):E60-E66.
68. Baumert TF, Wellnitz S, Aono S, et al. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology. 2000;32(3):610-617.
69. Pestka JM, Zeisel MB, Blaser E, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 2007;104(14):6025-6030. (Pubitemid 47175652)
70. von Hahn T, Yoon JC, Alter H, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology. 2007;132(2): 667-678. (Pubitemid 46274668)
71. Haberstroh A, Schnober EK, Zeisel MB, et al. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology. 2008;135(5):1719-1728.
72. Zhang P, Wu CG, Mihalik K, et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A. 2007;104(20):8449-8454. (Pubitemid 47175508)
73. Sandrin V, Boulanger P, Penin F, Granier C, Cosset FL, Bartosch B. Assembly of functional hepatitis Cvirus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J Gen Virol. 2005;86(Pt 12):3189-3199. (Pubitemid 41685150)
74. Lee S, Varano J, Flexman JP, et al.Decreased IP-10 and elevated TGFbeta1 levels are associatedwith viral clearance following therapy in patientswith hepatitisCvirus. DisMarkers. 2010;28(5):273-280.
75. Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr. 2007;45(3):262-268. (Pubitemid 47012371)
76. Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlateswith histological severity and lobular inflammation. J Leukoc Biol. 2003;74(3):360-369. (Pubitemid 38040396)
77. Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44(6):1617-1625. (Pubitemid 44953667)
78. Reiberger T, Aberle JH, Kundi M, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. AntivirTher. 2008;13(8):969-976.
79. Sugimoto R, Enjoji M,Nakamuta M, et al. Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells. Liver Int. 2005;25(2):420-428.
80. Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology. 2010;139(1):154-162.
81. Zeremski M, ShuMA, BrownQ, et al.HepatitisCvirus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat. 2009;16(1): 10-20.
82. Mizukoshi E, Rehermann B. Immune responses and immunity in hepatitis C virus infection. J Gastroenterol. 2001;36(12):799-808. (Pubitemid 34036902)
83. Golden-Mason L, Bambha KM, Cheng L, et al. Natural killer inhibitory receptor expression associatedwith treatment failure and interleukin-28B genotype in patientswith chronic hepatitis C.Hepatology. 2011;54(5): 1559-1569.
84. StegmannKA,BjorkstromNK,VeberH, et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology. 2010;138(5):1885-1897.
85. Ahlenstiel G, Edlich B,Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology. 2011;141(4):1231-1239.
86. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology. 2010;52(5):1581-1589.
87. Tsubouchi E, Akbar SM, Murakami H, Horiike N, Onji M. Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy. Clin Exp Immunol. 2004;137(2):417-423. (Pubitemid 39013090)
88. Wertheimer AM, Bakke A, Rosen HR. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology. 2004;40(2):335-345. (Pubitemid 39062851)
89. Dolganiuc A, Chang S, Kodys K, et al. Hepatitis C virus (HCV) core protein-induced, monocytemediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol. 2006;177(10):6758-6768. (Pubitemid 44715040)
90. Pachiadakis I, Chokshi S, Cooksley H, et al. Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. Clin Immunol. 2009;131(3):415-425.
91. Gowans EJ, Roberts S, Jones K, et al. A phase I clinical trial of dendritic cell immunotherapy inHCVinfected individuals. J Hepatol. 2010;53(4):599-607.
92. Hraber P, Kuiken C, Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology. 2007;46(6):1713-1721.
93. Kuniholm MH, Kovacs A, Gao X, et al. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology. 2010;51(5):1514-1522.
94. McKiernan SM, Hagan R, Curry M, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology. 2004;40(1):108-114. (Pubitemid 38877575)
95. Bosi I, Ancora G, Mantovani W, et al. HLA DR13 and HCV vertical infection. Pediatr Res. 2002;51(6):746-749. (Pubitemid 34547339)
96. Bevilacqua E, Fabris A, Floreano P, et al. Genetic factors in mother-to-child transmission of HCV infection. Virology. 2009;390(1):64-70.
97. Martinetti M, Pacati I, CucciaM, et al. Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus. Int J Immunopathol Pharmacol. 2006;19(2):369-378. (Pubitemid 44181959)
98. Ge D, Fellay J,Thompson AJ, et al.Genetic variation in IL28B predicts hepatitisCtreatment-induced viral clearance. Nature. 2009;461(7262):399-401.
99. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10):1105-1109.
100. Suppiah V,Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100-1104.
101. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338-1345.
102. Ruiz-Extremera A,Munoz-Gamez JA, Salmeron-RuizMA, et al.Genetic variation in interleukin 28B with respect to vertical transmission of hepatitisCvirus and spontaneous clearance inHCV-infected children. Hepatology. 2011;53(6):1830- 1838.
103. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut. 2011;60(9):1284-1293.
104. Witte K,GruetzG, VolkHD, et al.Despite IFN-lambda receptor expression, bloodimmune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009;10(8):702-714.
105. Kutscher S, Bauer T,Dembek C, Sprinzl M, Protzer U.Design of therapeutic vaccines: hepatitis B as an example.Microb Biotechnol. 2011;5(2):270-282.
106. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302(5645):659-662. (Pubitemid 37310924)
107. Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines. 2011;10(5):659-672.
108. Ray R,Meyer K, Banerjee A, et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis. 2010;202(6):862-866.
109. Wedemeyer H, Schuller E, Schlaphoff V, et al.Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine. 2009;27(37):5142-5151.
110. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV inman. Sci TranslMed. 2012;4(115):115ra1.
111. Dorner M,Horwitz JA, Robbins JB, et al. A genetically humanizedmouse model for hepatitis C virus infection. Nature. 2011;474(7350):208-211.
112. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology; 2002,122(2):352-365. (Pubitemid 34116987)
113. Naas T, Ghorbani M, Alvarez-Maya I, et al. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol. 2005;86(Pt 8):2185-2196. (Pubitemid 41057523)
114. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. NatMed. 2001;7(8):927-933. (Pubitemid 32756430)
115. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/- /Il2rg-/-mice. Nat Biotechnol. 2007;25(8):903-910. (Pubitemid 47236918)
116. Griffin S, Trowbridge R, Thommes P, et al. Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo. J Hepatol. 2008;49(6):908-915.
117. Yoshida T, Saito A, Iwasaki Y, et al. Characterization of natural killer cells in tamarins: a technical basis for studies of innate immunity. FrontMicrobiol. 2010;1:128.
118. Amako Y, Tsukiyama-Kohara K, Katsume A, et al. Pathogenesis of hepatitis C virus infection in Tupaia belangeri. J Virol. 2010;84(1):303-311.
119. Haller AA, Lauer GM, King TH, et al.Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007;25(8):1452-1463. (Pubitemid 46074294)
120. SallbergM, Frelin L,Weiland O. DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of amoving target. Expert Opin Biol Ther. 2009;9(7):805-815.
121. + T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. HumVaccin. 2009;5(3):151-157.
122. Yutani S, Yamada A, Yoshida K, et al. Phase I clinical study of a personalized peptide vaccination for patients infectedwith hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine. 2007;25(42):7429-7435. (Pubitemid 47484009)
123. Yutani S, Komatsu N, Shichijo S, et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci. 2009;100(10):1935-1942.